Revelation Biosciences, Inc.
REVBW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $9.99K in total; no superinvestor holds it.
Other share classesREVB
Q4 2022 vs. Q3 2022
How the institutions holding Revelation Biosciences, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 12 | 1 | 11 | 0 |
| Shares | 2.72M | 233.4K | 1.81M | −671.9K (−27.0%) |
| Value | $123.0K | $10.0K | $23.6K | −$89.4K (−79.2%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Revelation Biosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Flow Traders U.S. LLC | 15,159 | $0 | 0.00% |
Sold out (1)
Institutions that held Revelation Biosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| UBS Group AG | 5,124 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Revelation Biosciences, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Empery Asset Management, LP | 233,382 | $10.0K |